April 15, 1991 |
An important clue to the cause of memory loss associated with Alzheimer's disease has been discovered by researchers at City of Hope in Duarte. Biochemist Eugene Roberts and his City of Hope colleagues report today in the prestigious Proceedings of the National Academy of Sciences that injections of fragments of a brain protein called beta-amyloid into the brains of mice cause the animals to forget tasks they have just learned.
December 3, 2010 |
Disease-modifying treatments for Alzheimer's disease have proved elusive. However, a study in mice published this week suggests that a treatment strategy relying on gene therapy may be worth pursuing. Researchers at the Gladstone Institute of Neurological Disease in San Francisco found that mice and humans with Alzheimer's disease have unusually low levels of an enzyme called EphB2 in the parts of the brain that control memory. EphB2 plays an important role in fostering communication between brain cells.
CALIFORNIA | LOCAL
December 9, 1991 |
British scientists said last week that they had discovered a causal link between severe head injuries and Alzheimer's disease, a terminal brain disorder that afflicts an estimated 4 million elderly people in the United States. "It has been argued for a long time that Alzheimer's has several different causes. Our data is the first direct evidence that head injury may be one significant causative factor," said Dr. Gareth Roberts of London's St. Mary's Hospital Medical School.
January 22, 2007 |
Scientists have identified a gene that increases the risk for late-onset Alzheimer's and provides another clue into the complex mind-robbing disease. The gene -- SORL1 -- stands out because it's been tested in four ethnic groups and a form of it seems to confer a risk in all of them -- including North Europeans, Caribbean Latinos, African Americans and Israeli Arabs.
CALIFORNIA | LOCAL
July 8, 1999
Vaccination with a protein that plays a key role in Alzheimer's disease can halt progression of an Alzheimer's-like disorder in mice and may even reverse some of the symptoms, according to a report in today's Nature. The protein, called AN-1792, is a modified form of beta-amyloid peptide, one of the proteins found in the plaques and tangles in the brain characteristic of Alzheimer's disease.
November 27, 2012 |
A biological medication already widely used to treat plaque psoriasis may be able to slow the accumulation of amyloid plaques in the brain that are the hallmark of Alzheimer's disease, a new study has found. The same study found that in older mice with established Alzheimer's, this treatment approach, which suppresses the brain's immune reaction to beta amyloid, brought a marked improvement in cognitive function and may even halt or reverse early signs of Alzheimer's. The new study was published this week in the journal Nature Medicine.
October 22, 1999 |
Scientists at Amgen have isolated an elusive brain chemical believed to play a crucial role in the development of Alzheimer's disease. Reporting their findings in today's edition of Science, the researchers hope the discovery will lead to targeted treatments that can halt the advance of this mind-devouring disease that afflicts an estimated 4 million Americans.
August 19, 2013 |
New research finds that copper in amounts readily found in our drinking water, the foods we eat and the vitamin supplements we take likely plays a key role in initiating and fueling the abnormal protein build-up and brain inflammation that are hallmarks of Alzheimer's disease. While the mineral is important to healthy nerve conduction, hormone secretion and the growth of bones and connective tissue, a team of researchers from the University of Rochester Medical Center suggested that too much of it may be a bad thing, and they set about to explore copper's dark side.
March 25, 2002 |
A blood test may be able to identify Alzheimer's disease long before there are symptoms of the brain-destroying disorder, allowing early treatment, according to researchers from Washington University School of Medicine in St. Louis. The researchers reported in the March 22 Science that injecting an antibody into mice causes a sudden flood in the bloodstream of a protein that forms neuron-destroying plaques in the brain.
September 8, 1992 |
BioSource Industries Inc. of Camarillo has obtained worldwide marketing rights to a test kit for the measurement of Serum Amyloid A, a reagent used in diagnosing such diseases as rheumatoid arthritis as well as secondary infections associated with cystic fibrosis and AIDS. The kit gives BioSource "an excellent opportunity to market a unique test for what we believe could become a substantial market," said James Chamberlain, BioSource's chief executive officer.